Surgical versus non-surgical intervention in endometriosis with infertility: a patient preference trial

Hormonal suppression decrease pain and reduce endometrioma size in women with endometriosis. There are medications like cabergoline which reduce inflammation associated with endometriosis but do not prevent ovulation. Hormonal suppression followed by cabergoline may allow pregnancy in women with endometriosis. The objective of the study was to assess and compare the efficacy of medical versus surgical management in infertile women with endometriosis.

A patient preference clinical trial was carried out on 20 women who wish pregnancy and has sonographic evidence of endometrioma and pain. They were counseled adequately about the advantages and disadvantages of surgical and medical management of endometriosis with infertility and were asked to make a choice. The interventions were applied according to patient preference. The interventions were i) dienogest for 3 months when cyst size ≤5 cm and letrozole plus norethisterone for 6 months when cyst size > 5 cm followed by cabergoline 0.5 mg twice weekly for 6 months, plus timed intercourse and ii) laparoscopic surgery followed by expectant management or ovarian stimulation with or without intrauterine insemination. The women were followed up for results.

A total of 18 participants opted for medical management and only 2 participants for surgery. All participants given medical management had reduction of pain, and all except one had reduction of cyst size. Pregnancy occurred in 2 out of 14 (14.3%) participants given medication. One woman with surgery had persistence of pain and recurrence of cyst. No one having surgery got pregnant during the study period.

The infertile women with endometriosis prefer medical management over surgery. The medical management may be a better option for infertile women with endometriosis who do not plan in vitro fertilization in near future. Metrics

Giudice LC. Clinical practice. Endometriosis. N Engl J Medi. 2010;362(25):2389-98. Heather R, Quinivan A. Let's not forget endometriosis and infertility amid the Covid 19 crisis. J Psychos Obstetr Gynecol. 2020;41(2):83-5. Dunselman GA, Vermeulen N, Becker C, Calhaz-Georg C, D’Hoogie T, De Bie B, et al. ESHRE guideline management of women with endometriosis. Human Reproduct. 2014;29(3):400-12. Khine YM, Taniguchi F, Harada T. Clinical management of Endometriosis associated infertility. Reproduct Medi Biol. 2016;15:217-25. Keckstein J, Saridogan E, Ulrich UA, Sillem M, Oppelt P, Schweppe KW, et al. The Enzian Classification: a comprehensive non-invasive and surgical description system for endometriosis. Acta Obstetr Gynecolog Scandin. 2021;100(7):1165-75. Hwang H, Chung Y, Lee SR, Park H, Song J, Kim H et al. Clinical evaluation and management of endometriosis: guideline for Korean patients from Korean Society of Endometriosis. Obstetr Gynecol Sci. 2018;61(5):53-64. Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opi Pharmacother. 2018;19(10):1109-25. Barra F, Scala C, Mais V, Guerriero S, Ferrero S. Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investigat Drugs. 2018;27(5):445-58. Ishrat S, Deeba F, Anwary SA, Banu J, Fatima P. Treatment experiences of infertile women with endometriosis: a qualitative analysis. Ann Internat Med Dental Res. 2021;7(3):176-86. Kowalski CJ and Mrdjenovich AJ. Patient preference clinical trials: why and when they will sometimes be preferred. Perspect Biol Medi. 2013;56(1):18-35. Shi J, Tan X, Feng G, Zhuo Y, Jiang Z, Banda S, et al. Research advances in drug therapy of endometriosis. Front. Pharmacol. 2023;14:1199010. Verma A and Konje JC. Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients. Eur J Obstet Gynecol Reprod Biol. 2009;143(2):112- 5. Seal SL, Kamilya G, Mukherji J, De A, Ghosh D and Majhi AK. Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review. Fertil Steril. 2011;95(1):291-315. Abushahin F, Goldman KN, Barbieri E, Milad M, Rademaker A and Bulun SE. Aromatase inhibition for refractory endometriosis-related chronic pelvic pain. Fertil Steril. 2011;96(4):939-42. Madny EH. Efficacy of letrozole in treatment of endometriosis-related pain. Middle East Fertil Soc J. 2014;19(1):64-8. Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril. 2004;81(2):290-6. Remorgida V, Abbamonte HL, Ragni N, Fulcheri E and Ferrero S. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Steril. 2007;88(3):724-6. Ferrero S, Remorgida V, Venturini PL, Maggiore ULR. Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. Eur J Obstet Gynecol Reprod Biol. 2014;174:117-22. Agarwal SK and Foster WG. Reduction in endometrioma size with three months of aromatase inhibition and progestin add-back. Bio Med Res Int. 2015;2015(1):878517. Chwalisz K, Surrey E and Stanczyk FZ. The hormonal profile of norethindrone acetate: rationale for add back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Reprod Sci. 2012;19(6):563-71. Ansary SA, Ishrat S, Banu J, Fatima P, Nasreen F, Jahan I, et al. Evaluation of the effect of aromatase inhibitor in reducing the size of endometrioma. Int J Reproduct Contracept Obstetr Gynecol. 2021;10(4):1295-302. Brichant G, Laraki I, Henry L, Munaut C and Nisolle M. New therapeutics in endometriosis: a review of hormonal, non-hormonal, and non-coding RNA treatments. Int J Mol Sci. 2021;22(19):10498. Hamid AM, Madkour WA, Moawad A, Elzaher MA and Roberts MP. Does cabergoline help in decreasing endometrioma size compared to LHRH agonist? A prospective randomized study. Arch Gynecol Obstetr. 2014;290:677-82. Mukhopadhyay P, Kyal A, Mukhopadhyay A. Does cabergoline help in decreasing chronic pelvic pain due to endometriosis compared to medroxyprogesterone acetate? A prospective randomized study. J South As Federat Obstetr Gynaecol. 2015;10:167-9. Shume MM, Banu J, Ishrat S, Munira S, Uddin MJ and Sultana S. The effects of cabergoline compared to dienogest in women with symptomatic endometrioma. Fertil Reproduct. 2021;3(2):49-54. DiVasta AD, Stamoulis C, Gallagher JS, Laufer MR, and Hornstein MD. Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate. Fertil Steril Rep. 2021;2(4):2666-3341. Ishrat S, Deeba F, Anwary SA, Begum N, Banu J. Cabergoline versus dydrogesterone in infertile women with endometriosis: a parallel-design randomized clinical trial. Gynecol Obstetr. 2021;11(8):565. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Human Reproduct. 2013;28(6):1552-68. Vitali SG, La Rossa VL, Rapisarda AMC and Lagana AS. Endometriosis and Infertility: the impact on quality of life and mental health. J Endometri Pelvic Pain Disord. 2017;9(2):112-15. Dancet EAF, Ameye L, Sermeu W, Welkenhuysen M, Nelen WLDM, Tully L. The ENDOCARE questionnaire (ECQ): a valid and reliable instrument to measure the patient-centeredness of endometriosis care in Europe. Human Reproduct. 2011;26(11):2988-99. Vercellini P. Introduction: Management of endometriosis: moving toward a problem-oriented and patient-centered approach. Fertil Steril. 2015;104(4):0015-0282. Vercellini P, Somigliana E, Cortinovis I, Bracco B, de Braud L, Dridi D, et al. " You can't always get what you want": from doctrine to practicability of study designs for clinical investigation in endometriosis. BMC Wom Health. 2015;15:1-9. Metzemaekers J, van den Akker-van Marle ME, Sampat J, Smeets MJGH, English J, Thijs E, et al. Treatment preferences for medication or surgery in patients with deep endometriosis and bowel involvement-a discrete choice experiment. BJOG. 2022;129(8):1376-85. Bohn JA, Bullard KA, Rodriguez MI, Ecker AM. Stepwise approach to the management of endometriosis related dysmenorrhea, a cost effective analysis. Obstetr Gynecol. 2021;138(4):557-64.